Literature DB >> 20627738

Long-acting anticholinesterases for myasthenia gravis: synthesis and activities of quaternary phenylcarbamates of neostigmine, pyridostigmine and physostigmine.

Qian-Sheng Yu1, Harold W Holloway, Weiming Luo, Debomoy K Lahiri, Arnold Brossi, Nigel H Greig.   

Abstract

The N-monophenylcarbamate analogues of neostigmine methyl sulfate (6) and pyridostigmine bromide (8) together with their precursors (5), (7), and the N(1)-methylammonium analogues of (-)-phenserine (12), (-)-tolserine (14), (-)-cymserine (16) and (-)-phenethylcymserine (18) were synthesized to produce long-acting peripheral inhibitors of acetylcholinesterase or butyrylcholinesterase. Evaluation of their cholinesterase inhibition against human enzyme ex vivo demonstrated that, whereas compounds 5-8 possessed only marginal activity, 12, 14, 16 and 18 proved to be potent anticholinesterases. An extended duration of cholinesterase inhibition was determined in rodent, making them of potential interest as long-acting agents for myasthenia gravis. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20627738      PMCID: PMC2989343          DOI: 10.1016/j.bmc.2010.05.022

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  32 in total

Review 1.  Cation-pi interactions in ligand recognition and catalysis.

Authors:  Niki Zacharias; Dennis A Dougherty
Journal:  Trends Pharmacol Sci       Date:  2002-06       Impact factor: 14.819

2.  Specific targeting of acetylcholinesterase and butyrylcholinesterase recognition sites. Rational design of novel, selective, and highly potent cholinesterase inhibitors.

Authors:  Luisa Savini; Alessandra Gaeta; Caterina Fattorusso; Bruno Catalanotti; Giuseppe Campiani; Luisa Chiasserini; Cesare Pellerano; Ettore Novellino; Dawn McKissic; Ashima Saxena
Journal:  J Med Chem       Date:  2003-01-02       Impact factor: 7.446

Review 3.  Neurobiology of butyrylcholinesterase.

Authors:  Sultan Darvesh; David A Hopkins; Changiz Geula
Journal:  Nat Rev Neurosci       Date:  2003-02       Impact factor: 34.870

4.  Atomic structure of acetylcholinesterase from Torpedo californica: a prototypic acetylcholine-binding protein.

Authors:  J L Sussman; M Harel; F Frolow; C Oefner; A Goldman; L Toker; I Silman
Journal:  Science       Date:  1991-08-23       Impact factor: 47.728

5.  Physostigmine analogs anticholinesterases: effects of the lengthening of the N-carbamic chain on the inhibition kinetics.

Authors:  M Marta; F Gatta; M Pomponi
Journal:  Biochim Biophys Acta       Date:  1992-04-17

Review 6.  The incidence of myasthenia gravis: a systematic literature review.

Authors:  Anita McGrogan; Samantha Sneddon; Corinne S de Vries
Journal:  Neuroepidemiology       Date:  2010-02-02       Impact factor: 3.282

7.  Bioavailability of intranasal neostigmine: comparison with intravenous route.

Authors:  M Broggini; C Benvenuti; V Botta; A Fossati; M Valenti
Journal:  Methods Find Exp Clin Pharmacol       Date:  1991-04

Review 8.  Clinical pharmacokinetics of cholinesterase inhibitors.

Authors:  S M Aquilonius; P Hartvig
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

9.  A long-lasting cholinesterase inhibitor affecting neural and behavioral processes.

Authors:  M Brufani; C Castellano; M Marta; A Oliverio; P G Pagella; F Pavone; M Pomponi; P L Rugarli
Journal:  Pharmacol Biochem Behav       Date:  1987-03       Impact factor: 3.533

Review 10.  Acetylcholinesterase--new roles for an old actor.

Authors:  H Soreq; S Seidman
Journal:  Nat Rev Neurosci       Date:  2001-04       Impact factor: 34.870

View more
  4 in total

Review 1.  Presynaptic Deficits at Neuromuscular Junctions: A Specific Cause and Potential Target of Axonal Neuropathy in Type 2 Charcot-Marie-Tooth Disease.

Authors:  Gursimran Chandhok; Ming Shiuan Soh
Journal:  J Neurosci       Date:  2016-08-03       Impact factor: 6.167

Review 2.  Molecular Insights into Therapeutic Potentials of Hybrid Compounds Targeting Alzheimer's Disease.

Authors:  Ankit Jana; Arkadyuti Bhattacharjee; Sabya Sachi Das; Niraj Kumar Jha; Avani Srivastava; Akshpita Choudhury; Rahul Bhattacharjee; Swagata De; Asma Perveen; Danish Iqbal; Piyush Kumar Gupta; Saurabh Kumar Jha; Shreesh Ojha; Sandeep Kumar Singh; Janne Ruokolainen; Kavindra Kumar Kesari; Ghulam Md Ashraf
Journal:  Mol Neurobiol       Date:  2022-03-26       Impact factor: 5.682

Review 3.  Recent developments in the design and synthesis of benzylpyridinium salts: Mimicking donepezil hydrochloride in the treatment of Alzheimer's disease.

Authors:  Saghi Sepehri; Mina Saeedi; Bagher Larijani; Mohammad Mahdavi
Journal:  Front Chem       Date:  2022-09-26       Impact factor: 5.545

4.  Caffeine inhibits acetylcholinesterase, but not butyrylcholinesterase.

Authors:  Miroslav Pohanka; Petr Dobes
Journal:  Int J Mol Sci       Date:  2013-05-08       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.